Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
Adult patients with histologically proven diagnosis of pleural mesothelioma with advanced unresectable disease are eligible to be enrolled. Patients will be randomized 1:1 to receive Volrustomig (MEDI5752) + Carboplatin + Pemetrexed or the investigator's choice of platinum+Pemetrexed or Nivolumab+Ipilimumab, based on their histology.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participant must be ≥ 18 years at the time of screening
Histologically proven diagnosis of pleural mesothelioma with known histology (epithelioid vs. non-epithelioid)
Advanced unresectable disease that cannot be treated with curative surgery (with or without chemotherapy)
WHO/ECOG performance status of 0 or 1 with no deterioration (that is, ECOG PS\>1) over the previous 2 weeks prior to day of first dosing
Has measurable disease per modified RECIST1.1
Has adequate bone marrow reserve and organ function at baseline
You may not be if
As judged by the investigator, any condition that would interfere with evaluation of the investigational product or interpretation of participant safety or study results.
Active or prior documented autoimmune or inflammatory disorders
History of another primary malignancy with exceptions.
Uncontrolled intercurrent illness
Tuberculosis, hepatitis B (HBV) or hepatitis C (HCV), human immunodeficiency virus (HIV) infection that is not well controlled
Any concurrent chemotherapy, radiotherapy, investigational, biologic, or hormonal therapy for cancer treatment
